Site search

Clear filter
2892 results for '' found
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physicians Choice in Hormone Receptorpositive, HER2-negative Unresectable Locally Advanc
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physicians Choice in Hormone Receptorpositive, HER2-negative Unresectable Locally Advanc
/
Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy (NCT06706622)
Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy (NCT06706622)
/
Australasian COVID-19 Trial [ASCOT]: An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess Different Treatment Regimens on the Clinical, Virological and Immunologica
Australasian COVID-19 Trial [ASCOT]: An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess Different Treatment Regimens on the Clinical, Virological and Immunologica
/
A Phase 3, Multicenter, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of Navenibart in participants with Hereditary Angioedema (NCT06842823)
/
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Ulcerative
/
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease [AMALTHEA] (NCT06450197)
/
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein[a] (NCT05581303)
/
A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chron
/
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure Wi
/
First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction [PD] (ACTRN12625000159459)
/
6 7 8 9 10